Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Low THC marijuana refers to marijuana cigarettes containing a specific low concentration of delta-9-tetrahydrocannabinol (THC), in this context 1.98% THC, provided by the National Institute on Drug Abuse (NIDA) for clinical research. It was evaluated by the New York State Psychiatric Institute for its analgesic properties in daily marijuana smokers using the Cold-Pressor Test (CPT) model. THC, the primary psychoactive constituent, acts as a partial agonist at the CB1 and CB2 cannabinoid receptors. CB1 receptors are primarily located in the central nervous system and mediate the analgesic and psychoactive effects, while CB2 receptors are found mainly in the immune system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Low THC marijuana.